Analysis – Page 58 – Goldea Capital

XBP Global Schedules Conference Call for First Quarter 2026 Financial Results

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

IRVING, Texas, May 12, 2026 (GLOBE NEWSWIRE) — XBP Global Holdings, Inc. (“XBP Global” or “the Company”) (NASDAQ: XBP), a multinational technology and services company orchestrating mission-critical systems that enable hyper-automation and digital transformation, announced today that it will host a live conference call with the financial community on May 14, 2026 at 5:00 pm Eastern Time to discuss its first quarter 2026 financial results, accompanied by a live webcast. The press release announcing first quarter 2026 results will be issued after market close on May 14, 2026. Hosting the call will be Andrej Jonovic, Chief Executive Officer, Dejan Avramovic, Chief Financial Officer, and Mike Shufeldt, Chief Revenue Officer. Participant Call-In Registration: Participants who wish to join the conference by telephone must register using...

GrowGeneration Reports First Quarter 2026 Financial Results

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

Second Consecutive Quarter of Year-Over-Year Revenue Growth driven by Commercial B2B Sales Net Loss Improved by $4.5 million and Adjusted EBITDA Improved by $2.4 million Year-Over-Year, Reflecting Operating Leverage from Cost Actions Proprietary Brand Penetration Increased 500 Basis Points Year-Over-Year to 37.0% of Cultivation and Gardening Revenue $41.1 million in Cash, Cash Equivalents, and Marketable Securities with no Debt Company Reaffirms 2026 Outlook: Revenue of $162 million to $168 million and Approximately Breakeven Adjusted EBITDA(1) DENVER, May 12, 2026 (GLOBE NEWSWIRE) — GrowGeneration Corp. (NASDAQ: GRWG) (“GrowGeneration,” “GrowGen,” or the “Company”), one of the nation’s largest suppliers of specialty products for controlled environment agriculture (CEA), commercial cultivation, and retail garden centers, today...

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soon HOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb function) and all Type I error-controlled secondary endpoints GMP manufacturing facility fully operational; second-floor expansion well underway Chief Commercial Officer with direct DMD commercial experience expected to join the Company in the coming weeks Filed suit against Nippon Shinyaku Co., Ltd. and NS Pharma, Inc. seeking rescission of U.S. distribution agreement and preliminary injunction; FDA review and PDUFA date unaffected Cash balance of approximately $279 million expected to support operations into Q4 2027 Eligible for a Priority Review Voucher upon approval; PRV is transferable and monetizable, offering potential non-dilutive...

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

Next anticipated Revita® clinical data readouts are 1-year data from the REVEAL-1 Cohort in Q2 2026 and 1-year randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026 Early Q4 2026 timing for topline 6-month randomized data from the REMAIN-1 Pivotal Cohort and late Q4 2026 timing for potential FDA De Novo marketing application submission in post-GLP-1 weight maintenance reaffirmed Clinical Trial Application authorization of RJVA-001 first-in-human study in the Netherlands for T2D; first-in-human dosing anticipated in second half of 2026 reiterated Cash runway guidance into early 2027, beyond anticipated Pivotal data readout reiterated Conference call today at 4:30 p.m. ET BURLINGTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) — Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical stage metabolic therapeutics...

Correction: South Jersey Industries, Inc. Commences Tender Offer to Purchase for Cash Any and All of the Outstanding 2018 Series A 3.70% Remarketable Junior Subordinated Notes due 2031

Written by Customer Service on May 12, 2026. Posted in Public Companies.

Folsom, NJ, May 12, 2026 (GLOBE NEWSWIRE) — Media Contact: SJI Media Relations609-561-9000 ext. 4131 media@sjindustries.com FOR IMMEDIATE RELEASE South Jersey Industries, Inc. Commences Tender Offer to Purchase for Cash Any and All of the Outstanding 2018 Series A 3.70% Remarketable Junior Subordinated Notes due 2031 FOLSOM, NJ, May 12, 2026 – South Jersey Industries, Inc. (“SJI” or the “Company”) today announced it has commenced a cash tender offer (the “Tender Offer”) to purchase for cash any and all of its outstanding 2018 Series A 3.70% Remarketable Junior Subordinated Notes due 2031 (the “Notes”) from each registered holder of the Notes (each, a “Holder,” and collectively, the “Holders”) subject to the terms specified in the Offer to Purchase, dated May 12, 2026 (as it may be amended or supplemented from time to time, the...

Bright Mountain Media, Inc. Announces First Quarter 2026 Financial Results

Written by Customer Service on May 12, 2026. Posted in Public Companies.

Boca Raton, FL, May 12, 2026 (GLOBE NEWSWIRE) — Bright Mountain Media, Inc. (OTCID: BMTM) (“Bright Mountain”, or the “Company”), a global holding company with current investments in digital publishing, advertising technology, consumer insights, creative services, and media services, today announced its financial results for the first quarter ended March 31, 2026. “Q1 2026 underscores the strength and resilience of Bright Mountain’s operating model,” said Matthew Drinkwater, CEO of Bright Mountain Media. “Our diversified portfolio enables us to efficiently allocate capital toward our highest-momentum advertising technology assets while continuing to invest in product innovation across our marketing technology platform. This intentional balance supports consistent performance, improves operating...

Form 8.5 (EPT/RI) – Advanced Medical Solutions Group plc – Amendment

Written by Customer Service on May 12, 2026. Posted in Public Companies.

AMENDMENT – FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Name of exempt principal trader: Investec Bank plc(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Advanced Medical Solutions Group Plc(c) Name of the party to the offer with which exempt principal trader is connected: Investec is Advisor & Joint Broker to Advanced Medical Solutions Group plc(d) Date dealing undertaken: 11th May 2026(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party...

KOIL Energy Solutions Announces Dates for First Quarter Earnings Release and Conference Call

Written by Customer Service on May 12, 2026. Posted in Public Companies.

HOUSTON, May 12, 2026 (GLOBE NEWSWIRE) — Koil Energy Solutions, Inc. (OTCQB: KLNG), a specialist in deepwater energy production and distribution equipment and services, announced today that it will report its first quarter 2026 results on Friday, May 15, 2026, before the market opens. KOIL will host an investor conference call to review its first quarter 2026 results on Friday, May 15, 2026, at 10:00am Eastern Time. Interested parties may listen to the call through a webcast link or using the dial in numbers. (See below details.) PARTICIPANT WEBCAST LINK: https://edge.media-server.com/mmc/p/hcndufov PARTICIPANT DIALS:PARTICIPANT DIAL IN (TOLL FREE) 1-833-630-1956PARTICIPANT INTERNATIONAL DIAL IN 1-412-317-1837 The earnings release and a replay of the conference call will also be available on the Company’s website, www.koilenergy.com,...

Nuclear Diamond Batteries, Inc. (OTC: NDBI) Receives Second U.S. Patent Allowance Advancing Commercialization of Ultra-Long-Life Nuclear Diamond Battery Platform

Written by Customer Service on May 12, 2026. Posted in Public Companies.

Mesquite, NV, May 12, 2026 (GLOBE NEWSWIRE) — MESQUITE, Nev., May 12, 2026 (GLOBE NEWSWIRE) — Nuclear Diamond Batteries, Inc. (OTCID: NDBI) (“NDBI” or the “Company”), a developer of next-generation nuclear diamond battery technologies through its majority-owned subsidiary AtomiQ, Inc., today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for 19 claims under U.S. patent application No. 17/928,967 covering a specialized high-porosity electrode architecture designed for advanced nuclear diamond battery systems. The newly allowed patent relates to a metal-organic framework (“MOF”) electrode coated with carbon nano-onion structures to be engineered in order to significantly improve charge storage, energy transfer efficiency, and long-term stability within nuclear diamond...

Regarding the supplement of the agenda of the Annual General Meeting of Shareholders of AB “Novaturas”

Written by Customer Service on May 12, 2026. Posted in Public Companies.

By the initiative and decision of the Board of AB “Novaturas”, company code 135567698, with its registered office at A. Mickevičiaus st. 27, Kaunas, the Republic of Lithuania (hereinafter – the Company), the agenda of the Annual General Meeting of Shareholders of the Company to be held on 27 May 2026 (hereinafter – the Meeting), as indicated in the notice of convening the Meeting of 4 May 2026, has been supplemented with agenda items No 6 -10. Agenda of the Meeting (including its supplemented items):The Company’s consolidated management report for 2025. The independent auditor’s report on the Company’s audited annual financial statements and the Company’s consolidated financial statements for 2025. Approval of the Company’s audited annual financial statements and the Company’s consolidated financial statements for 2025. Consent to the...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals